维得利珠单抗用于治疗溃疡性结肠炎的研究进展

Research Progress of Vedolizumab in the Treatment of Ulcerative Colitis

溃疡性结肠炎(UC)是一种以反复发作的腹痛、腹泻及粘液脓血便为主要临床症状的慢性非特异性炎症性肠病,随着对其免疫发病机制的深入研究,治疗模式已从传统药物逐渐转向以炎症相关通路为作用靶点的生物制剂治疗方案,维得利珠单抗(VDZ)作为一种新型肠道选择性生物制剂,可特异性阻断α4β7整合素与黏膜地址素细胞黏附分子-1 (MAdCAM-1)间的相互作用,抑制T淋巴细胞向肠道黏膜迁徙,减轻肠道炎症反应。本文对维得利珠单抗治疗溃疡性结肠炎的作用机制、临床疗效和安全性作一综述。

Ulcerative colitis (UC) is a chronic non-specific inflammatory bowel disease with recurrent ab-dominal pain, diarrhea and mucopurulent stools as the main clinical symptoms, with the in-depth study of its immune pathogenesis, the treatment mode has gradually shifted from traditional drugs to biologics targeting inflammation-related pathways. Vedolizumab (VDZ) as a new enteric selective biologic, can specifically block the interaction between α4β7 integrin and mucosal address hormone cell adhesion molecule-1 (MAdCAM-1), inhibits the migration of T lymphocytes to the intestinal mucosa and reduces the intestinal inflammatory response. This article reviews the mechanism, clinical efficacy and safety of vedolizumab in the treatment of ulcerative colitis.